Summary of safety findings
| . | Total population (N = 60) . | Eltrombopag switched (n = 38) . | Romiplostim switched (n = 22) . |
|---|---|---|---|
| TEAE | 35 (58.3) | 20 (52.6) | 15 (68.2) |
| Serious TEAE | 6 (10.0) | 4 (10.5) | 2 (9.1) |
| Thrombocytopenia | 2 (3.3) | 2 (5.3) | 0 |
| Rectal hemorrhage | 1 (1.7) | 0 | 1 (4.5) |
| Sudden death | 1 (1.7) | 0 | 1 (4.5) |
| Osteoarthritis | 1 (1.7) | 1 (2.6) | 0 |
| Nephrolithiasis | 1 (1.7) | 1 (2.6) | 0 |
| AESI | 1 (1.7) | 0 | 1 (4.5) |
| Thrombotic events | 0 | 0 | 0 |
| Bleeding events | 1 (1.7) | 0 | 1 (4.5) |
| TEAE related to avatrombopag | 15 (25.0) | 9 (23.7) | 6 (27.3) |
| Thrombocytopenia | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Dyspepsia | 1 (1.7) | 0 | 1 (4.5) |
| Nausea | 1 (1.7) | 1 (2.6) | 0 |
| Vomiting | 1 (1.7) | 1 (2.6) | 0 |
| Fatigue | 2 (3.3) | 0 | 2 (9.1) |
| Influenza-like illness | 1 (1.7) | 0 | 1 (4.5) |
| Edema peripheral | 1 (1.7) | 1 (2.6) | 0 |
| Contusion | 2 (3.3) | 2 (5.3) | 0 |
| PC decreased | 1 (1.7) | 1 (2.6) | 0 |
| PC increased | 1 (1.7) | 1 (2.6) | 0 |
| Dizziness | 1 (1.7) | 0 | 1 (4.5) |
| Headache | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| Hypoesthesia | 1 (1.7) | 0 | 1 (4.5) |
| Paresthesia | 1 (1.7) | 0 | 1 (4.5) |
| Insomnia | 1 (1.7) | 1 (2.6) | 0 |
| Heavy menstrual bleeding | 1 (1.7) | 1 (2.6) | 0 |
| Severe TEAE | 8 (13.3) | 4 (10.5) | 4 (18.2) |
| Thrombocytopenia | 3 (5.0) | 2 (5.3) | 1 (4.5) |
| Rectal hemorrhage | 1 (1.7) | 0 | 1 (4.5) |
| Sudden death | 1 (1.7) | 0 | 1 (4.5) |
| Osteoarthritis | 1 (1.7) | 1 (2.6) | 0 |
| Headache | 1 (1.7) | 0 | 1 (4.5) |
| Nephrolithiasis | 1 (1.7) | 1 (2.6) | 0 |
| TEAE leading to avatrombopag discontinuation | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Thrombocytopenia | 1 (1.7) | 1 (2.6) | 0 |
| Headache | 1 (1.7) | 0 | 1 (4.5) |
| . | Total population (N = 60) . | Eltrombopag switched (n = 38) . | Romiplostim switched (n = 22) . |
|---|---|---|---|
| TEAE | 35 (58.3) | 20 (52.6) | 15 (68.2) |
| Serious TEAE | 6 (10.0) | 4 (10.5) | 2 (9.1) |
| Thrombocytopenia | 2 (3.3) | 2 (5.3) | 0 |
| Rectal hemorrhage | 1 (1.7) | 0 | 1 (4.5) |
| Sudden death | 1 (1.7) | 0 | 1 (4.5) |
| Osteoarthritis | 1 (1.7) | 1 (2.6) | 0 |
| Nephrolithiasis | 1 (1.7) | 1 (2.6) | 0 |
| AESI | 1 (1.7) | 0 | 1 (4.5) |
| Thrombotic events | 0 | 0 | 0 |
| Bleeding events | 1 (1.7) | 0 | 1 (4.5) |
| TEAE related to avatrombopag | 15 (25.0) | 9 (23.7) | 6 (27.3) |
| Thrombocytopenia | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Dyspepsia | 1 (1.7) | 0 | 1 (4.5) |
| Nausea | 1 (1.7) | 1 (2.6) | 0 |
| Vomiting | 1 (1.7) | 1 (2.6) | 0 |
| Fatigue | 2 (3.3) | 0 | 2 (9.1) |
| Influenza-like illness | 1 (1.7) | 0 | 1 (4.5) |
| Edema peripheral | 1 (1.7) | 1 (2.6) | 0 |
| Contusion | 2 (3.3) | 2 (5.3) | 0 |
| PC decreased | 1 (1.7) | 1 (2.6) | 0 |
| PC increased | 1 (1.7) | 1 (2.6) | 0 |
| Dizziness | 1 (1.7) | 0 | 1 (4.5) |
| Headache | 4 (6.7) | 3 (7.9) | 1 (4.5) |
| Hypoesthesia | 1 (1.7) | 0 | 1 (4.5) |
| Paresthesia | 1 (1.7) | 0 | 1 (4.5) |
| Insomnia | 1 (1.7) | 1 (2.6) | 0 |
| Heavy menstrual bleeding | 1 (1.7) | 1 (2.6) | 0 |
| Severe TEAE | 8 (13.3) | 4 (10.5) | 4 (18.2) |
| Thrombocytopenia | 3 (5.0) | 2 (5.3) | 1 (4.5) |
| Rectal hemorrhage | 1 (1.7) | 0 | 1 (4.5) |
| Sudden death | 1 (1.7) | 0 | 1 (4.5) |
| Osteoarthritis | 1 (1.7) | 1 (2.6) | 0 |
| Headache | 1 (1.7) | 0 | 1 (4.5) |
| Nephrolithiasis | 1 (1.7) | 1 (2.6) | 0 |
| TEAE leading to avatrombopag discontinuation | 2 (3.3) | 1 (2.6) | 1 (4.5) |
| Thrombocytopenia | 1 (1.7) | 1 (2.6) | 0 |
| Headache | 1 (1.7) | 0 | 1 (4.5) |
Data are presented as n (%).